EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy

Binru Cai, Duoduo Lv iD, Qiang Qiu, Wenju Xiong, Heyu Tang iD, Yixiao Bai, Sicheng Zhou, Yiguo Hu iD, Rifaat Safadi, Chengdi Wang, Lingyun Zhou iD

Cancers · 10.07.2026 · 18 (14) · 2224

DOI: 10.3390/cancers18142224 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.07.2026. Verfasst von Binru Cai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Bureau of Chengdu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality worldwide, is driven by complex interactions between genetic mutations and reversible epigenetic alterations. Among these, aberrant DNA methylation, histone modifications, and dysregulated noncoding RNAs (ncRNAs) play central roles in hepatocarcinogenesis, tumor progression, and therapy resistance. Epigenetic changes not only regulate key oncogenic pathways, including JAK/STAT and RAS, but also contribute to tumor immune evasion and heterogeneity. Unlike genetic mutations, epigenetic alterations are reversible, offering unique opportunities for therapeutic targeting. This review highlights recent advances in understanding the epigenetic landscape of HCC, identifies promising biomarkers for early detection and prognosis, and evaluates emerging epigenetic therapies (including DNMT, HDAC, and BET inhibitors as well as ncRNA-based strategies). Although these therapies have shown tumor-suppressive or treatment-sensitizing effects in preclinical models, their clinical translation remains limited by modest efficacy, small early-phase trials, treatment-related adverse events, and insufficient biomarker-guided patient selection. These insights may support more precise diagnostic and therapeutic strategies for HCC.

Schlagwörter

Stichwörter der Autor:innen

biomarkersepigenetic alterationsepigenetic therapyhepatocellular carcinomanoncoding RNAs

Autor:innen und Institutionen

  • Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, China.
  • Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Department of Head and Neck Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, Gainesville, FL 32611, USA.
  • State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
  • The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, P.O. Box 12000, Jerusalem 91120, Israel.

ORCID-Profile: Duoduo Lv, Heyu Tang, Yiguo Hu, Lingyun Zhou

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Bureau of Chengdu

Zitieren

APA

Cai, B., Lv, D., Qiu, Q., Xiong, W., Tang, H., Bai, Y., Zhou, S., Hu, Y., Safadi, R., Wang, C., & Zhou, L. (2026). Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy. Cancers, 18(14), 2224. https://doi.org/10.3390/cancers18142224

Vancouver

Cai B, Lv D, Qiu Q, Xiong W, Tang H, Bai Y, et al. Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy. Cancers. 2026;18(14):2224. doi:10.3390/cancers18142224

BibTeX
@article{Cai2026,
  author = {Cai, Binru and Lv, Duoduo and Qiu, Qiang and Xiong, Wenju and Tang, Heyu and Bai, Yixiao and Zhou, Sicheng and Hu, Yiguo and Safadi, Rifaat and Wang, Chengdi and Zhou, Lingyun},
  title = {Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2224},
  doi = {10.3390/cancers18142224}
}
Kostenlos starten →